Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
IMMUNIC, INC. shareholders approved Ratification of the selection of Baker Tilly Virchow Krause, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-28 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
Proposal 2: Ratification of Appointment of Baker Tilly Virchow Krause, LLP as Independent Registered Public Accounting Firm FOR AGAINST ABSTAIN BROKER NON-VOTES 25,469,440 75,616 71,300 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
IMMUNIC, INC. shareholders approved Election of Dr. Richard Rudick and Ms. Maria Törnsén as directors for a three year term expiring at the 2026 annual meeting of stockholders at the 2023-06-28 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
Proposal 1: Election of Directors NOMINEE FOR WITHHELD BROKER NON-VOTES Dr. Richard Rudick 19,855,497 109,841 5,651,018 Ms. Maria Törnsén 19,840,786 124,552 5,651,018
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
IMMUNIC, INC. shareholders approved Approve amendments to the Company's 2019 Omnibus Plan to (i) increase the number of common stock authorized for issuance by 4,440,000 shares to a total of 10,348,871 shares, and (ii) remove the evergreen provision at the 2023-06-28 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
Proposal 3: Approve Amendments To the Company’s 2019 Omnibus Plan FOR AGAINST ABSTAIN BROKER NON-VOTES 19,529,897 408,815 26,626 5,651,018
View on SEC.gov